Certest Presents Newly-Released SARS-CoV-2 Diagnostic Products at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 29 Sep 2021

Image: VIASURE Real Time PCR Detection Kit (Photo courtesy of CerTest Biotec)

CerTest Biotec (Zaragoza, Spain) introduced all the new releases developed by the company in recent months, especially its products focused on the diagnosis of SARS-CoV-2, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.

Among its new releases highlighted by CerTest at AACC 2021 were the VIASURE Tropical Panel I Real Time PCR Detection Kit designed for the specific and differentiation of Zika (ZIKV), Dengue (DENV), Chikungunya (CHIKV), West Nile (WNV), Yellow fever (YFV) and/or Mayaro (MYV) viruses; and the FOB Turbilatex non-invasive immunological test for bowel cancer screening.

CerTest’s new products for the diagnosis of SARS-CoV-2 that were exhibited at the event included the CerTest CLIA SARS-CoV-2 Plate which is an antigen detection product; the CerTest SARS-CoV-2 one step card test which is a colored chromatographic immunoassay for the qualitative detection of SARS-CoV-2 from nasopharyngeal swab samples from patients with sign and symptoms of COVID-19 infection; and the VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit for the qualitative detection of RNA from genetic mutations in the S gene (P681R, L452R and E484Q) from positive SARS-CoV-2 nasopharyngeal samples.

CerTest also used the event as a launching pad for its new Business Units: CerTest CLIA, BioSynProbes and CerTest Vaccines, which were represented at the company’s booth. According to the company, the new business units will complete the portfolio of comprehensive solutions not only for the diagnosis of infectious diseases, but also in the manufacturing processes of clinical tests and disease cure.

Related Links:
CerTest Biotec

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

Gold Member

Clinical Chemistry Assay

Sorbitol Dehydrogenase (SDH)

Electrolyte Analyzer

BKE-B

LAIR2 Antibody Pair Set

LAIR2 Antibody Pair [Biotin]

Latest AACC 2021 News

Channels

Clinical Chemistry

view channel

Blood Biomarker May Track Bone Metastases in Medullary Thyroid Cancer

Medullary thyroid cancer (MTC) is a rare malignancy that often progresses silently, frequently going undetected until it reaches advanced stages. By the time it spreads to bone, it can produce unusual... Read more

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Image: Findings show that low circulating ISM2 around 12 weeks gestation was the strongest indicator of later pregnancy complications (Image Credit: Adobe Stock)

New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction

Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more

Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction

Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read more

Molecular Diagnostics

view channel

Image: In the Fetal Extracellular Vesicle Monitoring of Oxygenation (FEMOx) project several of the Wyss Institute’s Technology Platforms and faculty labs join forces. Leveraging and integrating multiple of the Wyss Institute’s technological innovations and advanced analytical capabilities they aim develop a test that can rapidly and accurately detect fetal oxygen deprivation by detecting specific miRNA signatures in extracellular vesicles (EVs) that circulate in maternal blood. (Iimage Credit: Wyss Institute at Harvard University)

Project to Develop Maternal Blood Test for Rapid Fetal Oxygen Deprivation Detection

Intrapartum fetal hypoxia remains difficult to assess with existing monitoring, leaving clinicians to make time-critical decisions with incomplete data. Limited detection and interpretation can contribute... Read more

DPYD Genotyping Assay Supports Safer Fluoropyrimidine Chemotherapy Dosing

Fluoropyrimidine-based chemotherapy can lead to severe toxicity in patients with specific variants in the dihydropyrimidine dehydrogenase (DPYD) gene, making pre-treatment assessment a critical step in... Read more

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

FDA Clears Liquid Biopsy Test to Guide Earlier Breast Cancer Therapy Switch

Guardant360 CDx (Guardant Health, Inc.; Palo Alto, CA, USA) has been approved by the U.S. Food and Drug Administration (FDA) as a companion diagnostic to identify patients with hormone receptor (HR)-positive,... Read more

Hematology

view channel

Image: New findings indicate that people with borderline anemia—hemoglobin just above WHO anemia thresholds—face a higher mortality risk than those with higher hemoglobin levels within the normal range (Image Credit: 123RF)

Immunology

view channel

New Cellular Map May Help Predict Crohn’s Disease Course in Children

Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more

Temporal Immune Profiling Reveals How Sepsis States Change Over Time

Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more

Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19

Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read more

Gut “Memory” May Explain Why IBD Flares Return

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are characterized by recurring flare-ups that damage the intestinal mucosa and remain difficult to predict.... Read more

Microbiology

view channel

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more

Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs

Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more

Pathology

view channel

FDA Clearance Expands Digital Pathology Options for Clinical Laboratories

Hamamatsu Photonics K.K. (Hamamatsu, Japan) announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the NanoZoomer S20MD and NanoZoomer S540MD slide scanner systems.... Read more

Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples

Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more

Image: Graphical Abstract (Vivek Behera et al., Pan-tumor spatial transcriptomics reveals conserved properties of tumor organization, Cell Reports Medicine, 2026. DOI: 10.1016/j.xcrm.2026.103013)

AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer

Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read more

New Journal Addresses Evolving Needs in Clinical and Translational Pathology

Clinical pathology underpins diagnosis and therapy selection across oncology and other major diseases, but the field is rapidly evolving as new technologies reshape how disease is studied and classified.... Read more

Technology

view channel

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins

Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more

Autonomous Robotic System Receives FDA Authorization for Blood Collection

Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more

Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results

Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more

Industry

view channel

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers

Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio announced that Health Canada has issued Class II Medical Device Licenses for Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma for... Read more

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial

ANatera’s Signatera test will be used in a partnership with Angiex to evaluate patients receiving AGX101, a Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) in a Phase I clinical trial.... Read more

$Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)$

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more

See LabMedica in...

LabMedica

Certest Presents Newly-Released SARS-CoV-2 Diagnostic Products at AACC Clinical Lab Expo

Latest AACC 2021 News

Channels